{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:17:30Z","timestamp":1792700250301,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["1R01HL153384-01"],"award-info":[{"award-number":["1R01HL153384-01"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["T32-HL007853"],"award-info":[{"award-number":["T32-HL007853"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinejcf.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiac Failure"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.cardfail.2026.01.018","type":"journal-article","created":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T06:51:07Z","timestamp":1772347867000},"page":"1362-1372","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Sotagliflozin, suPAR, and Cardiovascular Outcomes in Patients With Diabetes and Heart Failure: A SOLOIST-WHF Ancillary Study"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4144-0160","authenticated-orcid":false,"given":"ANIS","family":"ISMAIL","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GRACE","family":"ERNE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ALEXI","family":"VASBINDER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CHRISTINA G.","family":"HUTTEN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BAHJAT Z.","family":"GHAZZAL","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"IAN","family":"PIZZO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KRISTEN MACHADO","family":"DIAZ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TONIMARIE CLAIRE","family":"CATALAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"THERESA","family":"FARHAT","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BRENNA","family":"KNOTT","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PENNELOPE","family":"KUNKLE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MICHAEL","family":"SZAREK","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MICHAEL J.","family":"DAVIES","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PHILIPPE GABRIEL","family":"STEG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BERTRAM","family":"PITT","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DEEPAK L.","family":"BHATT","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SALIM S.","family":"HAYEK","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cardfail.2026.01.018_bib0001","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2026.01.018_bib0002","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2026.01.018_bib0003","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2026.01.018_bib0004","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2026.01.018_bib0005","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2026.01.018_bib0006","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.117.028268","article-title":"Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease","volume":"137","author":"Wanner","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2026.01.018_bib0007","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2026.01.018_bib0008","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2026.01.018_bib0009","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2026.01.018_bib0010","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","article-title":"Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.cardfail.2026.01.018_bib0011","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1161\/CIRCULATIONAHA.121.054442","article-title":"Does SGLT1 inhibition add benefit to SGLT2 inhibition in type 2 diabetes?","volume":"144","author":"Pitt","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2026.01.018_bib0012","doi-asserted-by":"crossref","first-page":"4754","DOI":"10.1093\/eurheartj\/ehac417","article-title":"Does SGLT1 inhibition add to the benefits of SGLT2 inhibition in the prevention and treatment of heart failure?","volume":"43","author":"Pitt","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2026.01.018_bib0013","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2026.01.018_bib0014","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1007\/s40618-023-02162-9","article-title":"The anti-inflammatory and immunological properties of SGLT-2 inhibitors","volume":"46","author":"Bendotti","year":"2023","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.cardfail.2026.01.018_bib0015","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jchf.2023.08.007","article-title":"1+2 might be >2: SGLT inhibition in patients with heart failure or chronic kidney disease","volume":"12","author":"Pitt","year":"2024","journal-title":"JACC Heart Fail"},{"issue":"24","key":"10.1016\/j.cardfail.2026.01.018_bib0016","doi-asserted-by":"crossref","DOI":"10.1172\/JCI158788","article-title":"Increased soluble urokinase plasminogen activator levels modulate monocyte function to promote atherosclerosis","volume":"132","author":"Hindy","year":"2022","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cardfail.2026.01.018_bib0017","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nm.4242","article-title":"Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease","volume":"23","author":"Hahm","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.cardfail.2026.01.018_bib0018","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1056\/NEJMoa1506362","article-title":"Soluble urokinase receptor and chronic kidney disease","volume":"373","author":"Hayek","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.cardfail.2026.01.018_bib0019","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.008194","article-title":"Predicting mortality in African Americans with type 2 diabetes mellitus: soluble urokinase plasminogen activator receptor, coronary artery calcium, and high-sensitivity C-reactive protein","volume":"7","author":"Hayek","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cardfail.2026.01.018_bib0020","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ekir.2017.02.001","article-title":"Cardiovascular disease biomarkers and suPAR in predicting decline in renal function: a prospective cohort study","volume":"2","author":"Hayek","year":"2017","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.cardfail.2026.01.018_bib0021","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/nm.4362","article-title":"A tripartite complex of suPAR, APOL1 risk variants and alpha(v)beta(3) integrin on podocytes mediates chronic kidney disease","volume":"23","author":"Hayek","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.cardfail.2026.01.018_bib0022","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1038\/s41467-023-40165-5","article-title":"SuPAR mediates viral response proteinuria by rapidly changing podocyte function","volume":"14","author":"Wei","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.cardfail.2026.01.018_bib0023","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.cardfail.2022.08.010","article-title":"Soluble urokinase plasminogen activator receptor levels and outcomes in patients with heart failure","volume":"29","author":"Hayek","year":"2023","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2026.01.018_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2024.132071","article-title":"Prognostic performance of soluble urokinase plasminogen activator receptor for heart failure or mortality in Western and Asian patients with acute breathlessness","author":"Chew-Harris","year":"2024","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cardfail.2026.01.018_bib0025","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1007\/s11886-023-01991-7","article-title":"Role of soluble urokinase-type plasminogen activator receptor in cardiovascular disease","volume":"25","author":"Ismail","year":"2023","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.cardfail.2026.01.018_bib0026","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.4239\/wjd.v14.i12.1862","article-title":"Empagliflozin ameliorates diabetic cardiomyopathy probably via activating AMPK\/PGC-1\u03b1 and inhibiting the RhoA\/ROCK pathway","volume":"14","author":"Li","year":"2023","journal-title":"World J Diabetes"},{"key":"10.1016\/j.cardfail.2026.01.018_bib0027","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00395-022-00934-7","article-title":"Cardioprotection by selective SGLT-2 inhibitors in a non-diabetic mouse model of myocardial ischemia\/reperfusion injury: a class or a drug effect?","volume":"117","author":"Nikolaou","year":"2022","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.cardfail.2026.01.018_bib0028","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/ejhf.49","article-title":"Increased plasma level of soluble urokinase plasminogen activator receptor is associated with incidence of heart failure but not atrial fibrillation","volume":"16","author":"Borne","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2026.01.018_bib0029","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jchf.2016.12.008","article-title":"Soluble urokinase-type plasminogen activator receptor improves risk prediction in patients with chronic heart failure","volume":"5","author":"Koller","year":"2017","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cardfail.2026.01.018_bib0030","doi-asserted-by":"crossref","first-page":"3876","DOI":"10.1002\/ehf2.14071","article-title":"Biomarker prognostication across Universal Definition of Heart Failure stages","volume":"9","author":"Mohebi","year":"2022","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.cardfail.2026.01.018_bib0031","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1161\/CIRCRESAHA.116.308445","article-title":"Anti-inflammatory effects of metformin irrespective of diabetes status","volume":"119","author":"Cameron","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.cardfail.2026.01.018_bib0032","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0098923","article-title":"Unchanged plasma levels of the soluble urokinase plasminogen activator receptor in elective coronary artery bypass graft surgery patients and cardiopulmonary bypass use","volume":"9","author":"Gozdzik","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.cardfail.2026.01.018_bib0033","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/j.amjcard.2012.08.008","article-title":"Usefulness of soluble urokinase plasminogen activator receptor to predict repeat myocardial infarction and mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous intervention","volume":"110","author":"Lyngbaek","year":"2012","journal-title":"Am J Cardiol"}],"container-title":["Journal of Cardiac Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916426001053?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916426001053?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T08:30:10Z","timestamp":1786437010000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071916426001053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1071916426001053"],"URL":"https:\/\/doi.org\/10.1016\/j.cardfail.2026.01.018","relation":{},"ISSN":["1071-9164"],"issn-type":[{"value":"1071-9164","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sotagliflozin, suPAR, and Cardiovascular Outcomes in Patients With Diabetes and Heart Failure: A SOLOIST-WHF Ancillary Study","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiac Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cardfail.2026.01.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}